Inositol: history of an effective therapy for Polycystic Ovary Syndrome

被引:2
|
作者
Bizzarri, M. [1 ]
Carlomagno, G. [2 ]
机构
[1] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy
[2] LoLiPharma Srl, Dept Med, Rome, Italy
关键词
Inositol; Polycistic ovary syndrome; PCOS; D-CHIRO-INOSITOL; SPERM INJECTION CYCLES; IMPROVE OOCYTE QUALITY; IN-VITRO FERTILIZATION; DOUBLE-BLIND TRIAL; INSULIN-RESISTANCE; MYOINOSITOL SUPPLEMENTATION; OVULATION INDUCTION; OVERWEIGHT PATIENTS; NONOBESE PATIENTS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inositol is a physiological compound belonging to the sugar family. The two inositol stereoisomers, myo-inositol and D-chiroinositol are the two main stereisomers present in our body. Myo-inositol is the precursor of inositol triphosphate, a second messenger regulating many hormones such as TSH, FSH and insulin. D-chiroinositol is synthetized by an insulin dependent epimerase that converts myo-inositol into D-chiro-inositol. Polycistic Ovary Syndrome (PCOS) is a metabolic and hormonal disorder and a common cause of infertility. Insulin resistance and the consequent hyperinsulinaemia contribute to hyperandrogenism development, typical marker of PCOS. In these patients myo and/or D-chiro-inositol administration improves insulin sensivity while only myo-inositol is a quality marker for oocytes evaluation. Myo-inositol produces second messengers for FSH and glucose uptake, while D-chiroinositol provides second messengers promoting glucose uptake and glycogen synthesis. The physiological ratio of these two isomers is 40:1 (MI/DCI) and seems to be an optimal approach for the treatment of PCOS disorders.
引用
收藏
页码:1896 / 1903
页数:8
相关论文
共 50 条
  • [21] Effective regimens for ovulation induction in polycystic ovary syndrome
    Tapanainen, Juha S.
    Morin-Papunen, Laure
    POLYCYSTIC OVARY SYNDROME: CURRENT CONTROVERSIES, FROM THE OVARY TO THE PANCREAS, 2008, : 307 - 320
  • [22] Metabolic and hormonal effects of a combined Myo-inositol and D-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)
    Januszewski, Marcin
    Issat, Tadeusz
    Jakimiuk, Alicja A.
    Santor-Zaczynska, Malgorzata
    Jakimiuk, Artur J.
    GINEKOLOGIA POLSKA, 2019, 90 (01) : 7 - 10
  • [23] Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
    Dorina Greff
    Anna E. Juhász
    Szilárd Váncsa
    Alex Váradi
    Zoltán Sipos
    Julia Szinte
    Sunjune Park
    Péter Hegyi
    Péter Nyirády
    Nándor Ács
    Szabolcs Várbíró
    Eszter M. Horváth
    Reproductive Biology and Endocrinology, 21
  • [24] Family history as a risk factor for the polycystic ovary syndrome
    Azziz, R
    Kashar-Miller, MD
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2000, 13 : 1303 - 1306
  • [25] Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
    Greff, Dorina
    Juhasz, Anna E. E.
    Vancsa, Szilard
    Varadi, Alex
    Sipos, Zoltan
    Szinte, Julia
    Park, Sunjune
    Hegyi, Peter
    Nyirady, Peter
    Acs, Nandor
    Varbiro, Szabolcs
    Horvath, Eszter M. M.
    REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2023, 21 (01)
  • [26] The Rationale of the Myo-Inositol and D-Chiro-Inositol Combined Treatment for Polycystic Ovary Syndrome
    Dinicola, Simona
    Chiu, Tony T. Y.
    Unfer, Vittorio
    Carlomagno, Gianfranco
    Bizzarri, Mariano
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1079 - 1092
  • [27] In Vitro Effect of Inositol on Inflammatory Status of Erythrocytes in Polycystic Ovary Syndrome.
    Dona, G.
    Bordin, L.
    Fiore, C.
    Tibaldi, E.
    Sabbadin, C.
    Dallaca, A.
    Ambrosini, G.
    Andrisani, A.
    Giorgino, F. L.
    Clari, G.
    Armanini, D.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [28] Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome
    Lete, Inaki
    Martinez, Ainara
    Lasaga, Irene
    Centurion, Eva
    Vesga, Amaia
    GYNECOLOGICAL ENDOCRINOLOGY, 2024, 40 (01)
  • [29] Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
    Nestler, JE
    Jakubowicz, DJ
    Reamer, P
    Gunn, RD
    Allan, G
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17): : 1314 - 1320
  • [30] Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome
    Dona, Gabriella
    Sabbadin, Chiara
    Fiore, Cristina
    Bragadin, Marcantonio
    Giorgino, Francesco L.
    Ragazzi, Eugenio
    Clari, Giulio
    Bordin, Luciana
    Armanini, Decio
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (04) : 703 - 710